Report The Panel agreed on the outline of the 2027 IPCC Methodology Report on Carbon Dioxide Removal Technologies, Carbon Capture, Utilization, and Storage for National Greenhouse Gas Inventories (Additional guidance) at its 63rd Session held in Lima, Peru from 27-30 October 2025 (Decision IPCC-LXIII-6). The report will be a single Methodology Report comprising an Overview Chapter and six volumes consistent with the format of the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. The structure of the Methodology Report is consistent with the 2006 IPCC Guidelines so as to make it easier for inventory compilers to use this Methodology Report with the 2006 IPCC Guidelines. Topics that will be addressed include: Transport, injection and sequestering of CO2 in relation to enhanced oil, gas, and coal-bed methane recovery Production of products containing or derived from captured and/or removed CO2 Carbonation of cement and lime-based structures Soil carbon sinks and related emissions enhanced through biochar and weathering and other elements Coastal wetlands carbon dioxide removal types not in previous IPCC Guidelines as well as additional information on mangroves, tidal marshes and seagrass in coastal waters Durable biomass products Carbon dioxide capture from combustion and process gases Direct air capture Carbon dioxide utilisation Carbon dioxide transport including cross border issues Carbon dioxide injection and storage CO2 removal through direct capture of CO2 from water already processed by inland and coastal facilities; and related elements across the range of categories of the IPCC Guidelines. The national greenhouse gas inventory includes sources and sinks occurring within the territory over which a country has jurisdiction. Over 150 experts are expected to participate in the writing process, which will be completed by 2027. The participants will be selected by the Task Force Bureau taking into account scientific and technical expertise, geographical and gender balance to the extent possible in line with Appendix A to the Principles Governing IPCC Work. The First Lead Authors’ meeting will be held in Rome, Italy, in April 2026. Preparatory Work The decision by the Panel to prepare this Methodology Report was informed by the work of experts at the scoping meeting held in Copenhagen, Denmark, from 14-16 October 2024. Prior to the scoping meeting, an expert meeting was held at Vienna, Austria 1-3 July 2024. These meetings considered Carbon Dioxide Removal (CDR) methods mentioned in the AR6 WGIII Report as a starting point for discussion and noted that several CDR activities have been already covered by the existing IPCC Guidelines. More Information The IPCC Secretary has written to national government focal points inviting nominations of authors by 12 December 2025.

Fast Facts Medicaid programs that cover prescription drugs are generally required to cover drugs that are (1) FDA approved and (2) made by a manufacturer that participates in the Medicaid Drug Rebate Program. 13 Medicaid programs didn’t cover Mifeprex and its generic equivalent, Mifepristone Tablets, 200 mg, when required. These drugs are used for medical abortion. We recommended the Centers for Medicare & Medicaid Services ensure Medicaid programs comply with federal requirements for covering Mifepristone Tablets, 200 mg. We also reiterated our 2019 recommendation on Mifeprex, which hasn’t been implemented. White pills spilling from a pill bottle. Skip to Highlights Highlights What GAO Found Medicaid programs that choose to cover outpatient prescription drugs are required to cover all Food and Drug Administration (FDA) approved drugs for their medically accepted indications when those drugs are made by a manufacturer that participates in the Medicaid Drug Rebate Program (MDRP), except as outlined in federal law. The FDA has approved two drugs—Mifeprex in 2000 and its generic equivalent in 2019, referred to as Mifepristone Tablets, 200 mg—for the medical termination of an intrauterine pregnancy, known as a medical abortion. Danco Laboratories and GenBioPro are the exclusive manufacturers of Mifeprex and Mifepristone Tablets, 200 mg, respectively, and both manufacturers participate in the MDRP. Medicaid programs in all 50 states, the District of Columbia, and Puerto Rico cover prescription drugs and participate in the MDRP. According to officials from the Centers for Medicare & Medicaid Services (CMS)—the federal agency within the Department of Health and Human Services (HHS) responsible for ensuring Medicaid programs’ compliance—none of the MDRP’s statutory exceptions apply to Mifeprex or Mifepristone Tablets, 200 mg. Thus, these 52 Medicaid programs must cover these drugs when prescribed for medical abortion in circumstances eligible for federal funding, such as when the pregnancy is the result of rape or incest. GAO identified gaps in Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg. Officials from 35 of the 49 programs who responded to GAO questions said their programs covered Mifeprex and Mifepristone Tablets, 200 mg for medical abortion, as of December 31, 2024. In contrast, officials from 13 programs told GAO their programs did not cover either drug for medical abortion. An official from the remaining program did not specify the medical indications for which its program covered the drugs. Medicaid Programs’ Coverage of Danco Laboratories’ Mifeprex and GenBioPro’s Mifepristone Tablets, 200 mg, as of December 31, 2024 Note: For more details, see fig. 1 in GAO-25-107911. State officials’ responses to GAO’s questions indicated that some states may not be complying with the MDRP requirements for covering Mifeprex and Mifepristone Tablets, 200 mg. However, CMS has not determined the extent to which states comply with the MDRP requirements for these drugs. CMS officials told GAO they were not aware of the following: Nine programs did not cover Mifeprex and Mifepristone Tablets, 200 mg for any medical indication, as of December 31, 2024; GAO reported four of these programs did not cover Mifeprex in 2019. Mifepristone Tablets, 200 mg was not available at the time of GAO’s 2019 report. Four additional Medicaid programs did not cover either drug when prescribed for medical abortion, as of December 31, 2024. CMS was not aware of these coverage gaps, in part, because it had not implemented GAO’s 2019 recommendation to take actions to ensure Medicaid programs comply with MDRP requirements to cover Mifeprex. CMS also has not taken actions related to the coverage of Mifepristone Tablets, 200 mg, as of August 2025. Without such actions, CMS lacks assurance that Medicaid programs comply with MDRP requirements and Medicaid beneficiaries may lack access to these drugs when appropriate. Why GAO Did This Study GAO was asked to describe Medicaid programs’ coverage of mifepristone. This report examines Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg, among other things. GAO reviewed laws and CMS guidance on the MDRP, and coverage of Mifeprex and Mifepristone Tablets, 200 mg. GAO also sent written questions to officials from the 52 Medicaid programs that participate in the MDRP regarding their coverage of these drugs, and reviewed officials’ responses from the 49 programs that provided GAO information. Recommendations GAO reiterates its 2019 recommendation that CMS take actions to ensure states’ compliance with MDRP requirements to cover Mifeprex. GAO also recommends that CMS determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro’s Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. In response to the recommendation, HHS noted it is reviewing applicable law and will determine the best course of action to address it moving forward. Recommendations for Executive Action Agency Affected Recommendation Status Centers for Medicare & Medicaid Services The Administrator of CMS should determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro's Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. (Recommendation 1) Open Actions to satisfy the intent of the recommendation have not been taken or are being planned. When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information. Full Report Full Report (11 pages)

05.12.2025 – The European Scientific Advisory Board on Climate Change, established under the European Climate Law, will continue to be supported in its second term (2026-2030) by Ottmar Edenhofer. The Director of the Potsdam Institute for Climate Impact Research (PIK) has now been appointed by the Management Board of the European Environment Agency in Copenhagen for another four-year term on the Advisory Board, beginning on 24 March 2026. Advising EU policymakers on the path to the declared goal of climate neutrality: PIK Director Ottmar Edenhofer. Photo: PIK/Karkow The Advisory Board gives independent advice and produces reports on EU policies, and their coherence with the Climate Law and the EU’s commitments under the Paris Agreement. It consists of 15 high-level scientific experts covering a wide range of relevant fields. Edenhofer is serving as the Advisory Board’s current Chair during its first term (2022-2026). Highlights during this period have included scientific recommendations for an ambitious EU climate target for 2040, an analysis of the action needed to achieve climate neutrality, and a study on scaling up atmospheric carbon removals. “I am very thankful for the great opportunity to continue supporting EU climate policy in this service role for the next four years,” says Edenhofer, who is also Professor for The Economics and Politics of Climate Change at the Technische Universität Berlin. “The European Union has taken some important steps in recent years towards its declared goal of climate neutrality by 2050. It remains important to make climate policy cost-effective, socially balanced and consistent with the requirements of an internationally competitive economy. As a member of the Advisory Board, I will do my best to provide scientific advice to policymakers on this task.” The composition of the Advisory Board for the next four-year term has now been decided through an open, fair and transparent selection process lasting several months. The decision on who will chair the body in future is not expected until beginning of the second term. The other members of the Advisory Board in the second term are: • Annela Anger-Kraavi – University of Cambridge • Constantinos Cartalis – National and Kapodistrian University of Athens • Suraje Dessai – University of Leeds’ School of Earth, Environment, and Sustainability • Laura Díaz Anadón – University of Cambridge • Vera Eory – Scotland’s Rural College • Lena Kitzing - Technical University of Denmark • Kati Kulovesi – University of Eastern Finland • Lars J. Nilsson – Lund University • Åsa Persson – KTH Royal Institute of Technology’s Climate Action Centre • Keywan Riahi – International Institute for Applied Systems Analysis • Jean-François Soussana – French National Research Institute for Agriculture, Food and the Environment • Giorgio Vacchiano – University of Milan • Detlef van Vuuren – PBL Netherlands Environmental Assessment Agency • Zinta Zommers – University of Toronto

Join us for Geo-Explorers, our brand new after-school kids’ club for children aged eight to eleven based at our main campus in Keyworth, Nottinghamshire. The clubs run in five-week cohorts and cost £30 for all five sessions. Courses will run between 16:00 and 17:00 on: Programme 1 – 25 February to 25 March Programme 2 – 22 April to 20 May Relative topics public engagement

Abstract Colorectal cancer liver metastasis (CRLM) is a leading cause of mortality, driven by poorly defined molecular interactions within the hepatic niche. Here, we identify a distinct population of pro-metastatic Early Growth Response 1 (Egr1)+ neutrophils that accumulate in the pre-metastatic liver. Mechanistically, we show that KIAA1199-high cancer cells secrete granulin-rich extracellular vesicles, which are internalized by hepatocytes. This uptake triggers a subset of functionally reprogrammed hepatocytes, characterized by a profound metabolic reprogramming and the suppression of peroxisome proliferator-activated receptor gamma (PPARγ) signaling, leading to increased secretion of Serum Amyloid A2 (SAA2). Hepatocyte-derived SAA2 subsequently activates Formyl Peptide Receptor 2 (FPR2) on neutrophils, stabilizing Egr1-driven transcriptional program via the PI3K-AKT pathway to enhance neutrophil survival and pro-angiogenic activity. These Egr1+ neutrophils co-localize with reprogrammed hepatocytes at the tumor-liver interface, where they promote vascular remodeling to facilitate metastatic colonization. Pharmacological restoration of PPARγ or FPR2 inhibition abrogate CRLM in preclinical models in female mice. Furthermore, a combined KIAA1199-SAA2 signature predicts liver metastasis risk in patients. Our findings delineate a KIAA1199-PPARγ/SAA2-Egr1 axis orchestrating the pre-metastatic niche and propose metabolic normalization as a preventative strategy for liver metastasis.

Abstract Butenolides are important features of many bioactive compounds. Current petrochemical-based methods for asymmetric butenolide synthesis are unsustainable. Biocatalysis could enable cheaper, greener, and more sustainable alternatives. However, known butenolide biosynthetic pathways are complex and challenging to harness. Here we show that avenolide, a 4-alkylbutenolide that regulates avermectin production in Streptomyces avermitilis, is assembled from a fatty acyl thioester by a multifunctional flavoenzyme and an iterative cytochrome P450. The flavoenzyme catalyzes homochiral 4-alkylbutenolide formation via successive desaturation, hydroxylation, and lactonization reactions, using dioxygen as the sole stoichiometric reagent. This lays the foundation for development of sustainable biocatalytic asymmetric butenolide synthesis.

Abstract Prostate cancer cells of different anatomical locations display remarkable heterogeneity. This poses a challenge to the clinical relevance of pre-clinical models and the efficacy of contemporary therapeutic approaches. Here we develop the snFLARE-seq and mxFRIZNGRND methodologies to directly investigate the transcriptomic and metabolomic landscape of prostate cancer patients utilizing formalin-fixed paraffin-embedded (FFPE) specimens. A retrospective analysis reveals the clinical disparities of prostate cancer from peripheral zone (PZ), transition zone (TZ), and across PZ and TZ. The snFLARE-seq, refined for enhanced single-nucleus sequencing, unveils distinct cell type distributions and signaling pathways between PZ and TZ samples. Hormone therapy substantially affects cancer cells and microenvironment, leading to a polarized feature of epithelial cells and a subverted immune microenvironment. With improvements in metabolite extraction, mxFRIZNGRND reveals unique metabolic features of prostate cancer from different origins. The metabolomic results indicate that PZ cancer cells are in a metabolic-dormant status, which are probably awaken by hormone therapy. Integrative analysis of results from snFLARE-seq, mxFRIZNGRND, and TCGA database uncovers four metabolic pathways and related genes associated with disease aggressiveness. Our work could accelerate investigations on disease heterogeneity and evolution in real-world clinical settings, stimulating patient-specific precision healthcare solutions.